Table 2.
Patients’ demographics and disease characteristics.
| PARAMETER | Gefitinib Only No. of Patients | Gefitinib + IL-2 No. of Patients | AllPatients | |
|---|---|---|---|---|
| Demographic characteristics | ||||
| Number of patients | 39 (56%) | 31 (44%) | 70 | |
| Males | 28 (72%) | 17 (55%) | 45 (64%) | |
| Females | 11 (28%) | 14 (45%) | 25 (36%) | |
| Age, years | ||||
| Median | 71 | 69 | 70 | |
| Range | 39–84 | 44–80 | 39–84 | |
| ECOG PS | ||||
| 0 | 14 (36%) | 17 (55%) | 31 (44%) | |
| 1 | 17 (44%) | 13 (42%) | 30 (43%) | |
| ≥ 2 | 8 (20%) | 1 (3%) | 9 (13%) | |
| Smoking History | ||||
| Yes | 35 (90%) | 23 (74%) | 58 (83%) | |
| No | 3 (8%) | 7 (23%) | 10 (14%) | |
| Unknown | 1 (2%) | 1 (3%) | 2 (3%) | |
| Histology | ||||
| Adenocarcinoma | 24 (62%) | 24 (77%) | 48 (69%) | |
| Squamous cell carcinoma | 5 (13%) | 3 (10%) | 8 (11%) | |
| Bronchoalveolar-cell | 2 (5%) | 2 (6%) | 4 (6%) | |
| Undifferentiated | 8 (20%) | 2 (6%) | 10 (14%) | |
| Number of disease sites | ||||
| 1–2 | 12 (31%) | 9 (29%) | 21 (30%) | |
| ≥3 (range 3–8) | 27 (69%) | 22 (71%) | 49 (70%) | |
| Lung disease | ||||
| Yes | 37 (95%) | 30 (97%) | 67 (96%) | |
| No | 2 (5%) | 1 (3%) | 3 (4%) | |
| Liver metastasis | ||||
| Yes | 10 (26%) | 1 (3%) | 11 (16%) | |
| No | 29 (74%) | 30 (97%) | 59 (84%) | |
| Bone metastasis | ||||
| Yes | 12 (31%) | 12 (39%) | 24 (34%) | |
| No | 27 (69%) | 19 (61%) | 46 (66%) | |
| Node metastasis | ||||
| Yes | 26 (66%) | 18 (58%) | 44 (63%) | |
| No | 13 (33%) | 13 (42%) | 26 (37%) | |
| Adrenal metastasis | ||||
| Yes | 5 (13%) | 4 (13%) | 9 (13%) | |
| No | 34 (87%) | 27 (87%) | 61 (87%) | |
| Brain metastasis | ||||
| Yes | 8 (21%) | 5 (16%) | 14 (20%) | |
| No | 31(79%) | 26 (84%) | 56 (80%) | |
| Previous Chemotherapy for metastatic disease | ||||
| One line | 31 (79%) | 22 (71%) | 53 (76%) | |
| Two lines | 6 (15%) | 7 (23%) | 13 (18%) | |
| Three lines | 2 (5%) | 2 (6%) | 4 (6%) | |
| Previous platinum therapy | ||||
| Yes | 34 (87%) | 30 (97%) | 64 (91%) | |
| No | 5 (13%) | 1 (3%) | 6 (9%) | |
| Further therapy after progressive disease on treatment study | ||||
| Yes | 9 (23%) | 13 (42%) | 22 (31%) | |
| No | 30 (77%) | 18 (58%) | 48 (69%) |
ECOG PS: Eastern Cooperative Oncology Group Performance Status.